Literature DB >> 28327998

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Penault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton, E Winer.   

Abstract

Entities:  

Year:  2017        PMID： 28327998      PMCID： PMC5834023          DOI： 10.1093/annonc/mdx036

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
Ann Oncol 2016; 28(1): 16–33 (doi: 10.1093/annonc/mdw544) In the original article, author F. Penault-Llorca’s name was incorrectly written as F. Pernault-Llorca. This has been corrected online.
  46 in total

Review 1.  Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.

Authors:  Maureen P McEvoy; Jeffrey Landercasper; Himani R Naik; Sheldon Feldman
Journal:  Gland Surg       Date:  2018-12

Review 2.  Hepatic Metastasis from Breast Cancer.

Authors:  Ariel N Liberchuk; Amy R Deipolyi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

3.  Use of helical tomotherapy in locally advanced and/or metastatic breast cancer for locoregional treatment.

Authors:  Laura Thery; Alexandre Arsene-Henry; Susan Carroll; Dominique Peurien; Louis Bazire; Magalie Robilliard; Alain Fourquet; Youlia M Kirova
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

4.  Long-responders to anti-HER2 therapies: A case report and review of the literature.

Authors:  Luca Cantini; Mirco Pistelli; Agnese Savini; Lucia Bastianelli; Arianna Della Mora; Filippo Merloni; Michela Burattini; Rossana Berardi
Journal:  Mol Clin Oncol       Date:  2017-11-08

5.  Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Authors:  Elena Galve-Calvo; Eva González-Haba; Joana Gostkorzewicz; Irene Martínez; Alejandro Pérez-Mitru
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-14

6.  The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Min He; Cheng Liu; Qin Shi; Yuyun Sun; Yongping Zhang; Xiaoping Xu; Huiyu Yuan; Yingjian Zhang; Yin Liu; Guangyu Liu; Genhong Di; Zhongyi Yang; Zhonghua Wang; Zhiming Shao
Journal:  Oncologist       Date:  2020-04-28

Review 7.  Exploring the concepts and practices of advanced breast cancer treatment: a narrative review.

Authors:  Xiaojia Wang; Xiying Shao; Jian Huang; Lei Lei; Yuan Huang; Yabing Zheng; Wenming Cao; Zhanhong Chen
Journal:  Ann Transl Med       Date:  2021-04

8.  Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.

Authors:  Zheling Chen; Xiao Wang; Xiao Li; Yucheng Zhou; Ke Chen
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

9.  Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.

Authors:  Marina Elena Cazzaniga; Claudio Verusio; Mariangela Ciccarese; Alberto Fumagalli; Donata Sartori; Maria Rosaria Valerio; Mario Airoldi; Gabriella Moretti; Corrado Ficorella; Lorenzo Gianni; Andrea Michelotti; Alberto Zambelli; Antonio Febbraro; Daniele Generali; Mirco Pistelli; Ornella Garrone; Antonino Musolino; Patrizia Vici; Michela Maur; Lucia Mentuccia; Nicla La Verde; Giulia Valeria Bianchi; Salvatore Artale; Livio Blasi; Michelino De Laurentiis; Francesco Atzori; Anna Turletti; Mauro Porpiglia; Daniele Santini; Alessandra Fabi; Vittorio Gebbia; Alessio Schirone; Raffaella Palumbo; Antonella Ferzi; Antonio Frassoldati; Claudio Scavelli; Luca Clivio; Monica Giordano; Michela Donadio; Laura Biganzoli; Lucia Del Mastro; Giancarlo Bisagni; Lorenzo Livi; Clara Natoli; Filippo Montemurro; Ferdinando Riccardi; Emanuela Romagnoli; Paolo Marchetti; Valter Torri; Paolo Pronzato; Giorgio Mustacchi
Journal:  Breast Care (Basel)       Date:  2019-04-17       Impact factor: 2.860

10.  Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series.

Authors:  Alexandre Huber; Stéphanie J Seidler; Daniela E Huber
Journal:  Eur J Breast Health       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.